Calidi Biotherapeutics (CLDI) Retained Earnings (2021 - 2025)
Calidi Biotherapeutics' quarterly Retained Earnings came in at -$13000.0 in Q4 2025, up 53.57% year-on-year from -$8465.1 in Q4 2024, and up 99.99% quarter-over-quarter from -$137.6 million in Q3 2025.
Calidi Biotherapeutics has reported Retained Earnings for 5 years, with the latest figure at -$13000.0 in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings rose 53.57% year-over-year to -$13000.0; the trailing twelve-month figure through Dec 2025 stood at -$13000.0 (up 53.57% YoY), and the FY2025 full-year result was -$13000.0, up 53.57% from the prior year.
- Retained Earnings for Q4 2025 stood at -$13000.0, up from -$137.6 million in the prior quarter.
- The five-year high for Retained Earnings was $11000.0 in Q1 2024, with the low at -$137.6 million in Q3 2025.
- Average Retained Earnings over 5 years is -$49.6 million, with a median of -$13.2 million recorded in 2022.
- Year-over-year, Retained Earnings surged 100.14% in 2024 and slumped 1151918.18% in 2025.
- Tracing CLDI's Retained Earnings over 5 years: stood at -$14.7 million in 2021, then sank by 379.02% to -$70.4 million in 2022, then tumbled by 41.53% to -$99.6 million in 2023, then soared by 99.97% to -$28000.0 in 2024, then surged by 53.57% to -$13000.0 in 2025.
- The last three Retained Earnings figures came in at -$13000.0 (Q4 2025), -$137.6 million (Q3 2025), and -$132.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 36.42 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | 130.89 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | -13,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -13,000.00 |
| Sep 30, 2025 | -137.60 Mn |
| Jun 30, 2025 | -132.42 Mn |
| Mar 31, 2025 | -126.70 Mn |
| Dec 31, 2024 | -28,000.00 |
| Sep 30, 2024 | -117.60 Mn |
| Jun 30, 2024 | -27,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | -99.57 Mn |
| Sep 30, 2023 | -91.30 Mn |
| Jun 30, 2023 | -12.15 Mn |
| Mar 31, 2023 | -7.88 Mn |
| Dec 31, 2022 | -70.36 Mn |
| Sep 30, 2022 | -9.90 Mn |
| Jun 30, 2022 | -9.24 Mn |
| Mar 31, 2022 | -13.24 Mn |
| Dec 31, 2021 | -14.69 Mn |